Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: EZLibra who wrote (2946)	3/23/1999 9:21:00 PM
From: Maurice Winn	Read Replies (1) \| Respond to of 3702

Cu67 instead of I131 in Oncolym This gives better clinical results with less marrow damage. Check it out here: aacr.edoc.com The Oncolym licence seems not to have been the tonic TCLN needed [in terms of share price response anyway]. Since TCLN is again below $1, I should mention a reverse split as an option to maintain listing and the other 7 benefits. I bet there are new readers who haven't thought of it. That should cheer up some old hands. Meanwhile, the funereal pace of getting cancer treatments to market is dismaying. If IDEC was to buy TCLN and the two combined forces, there would be better progress and better return to shareholders of both companies. IDEC has the market capitalisation and lots of staff. TCLN has some technology, some good staff but is duplicating many expenses. Handling a lymphoma portfolio in under one effective management would strength the chances of sick people being treated quickly and effectively as well getting that treatment ready quickly and at least cost. These are not strictly competitors because the selection of the products doctors use will depend on clinical outcomes. They don't really overlap. If Rituxan is the best treatment, then Oncolym won't be considered. In the same way, if Oncolym is best, then Rituxan won't be. What if a combination, with CHOP, is best? We need research on that and a single management is more likely to get to the answer quickly. Maurice